Hematología y Hemoterapia

Resultados: 393
Tipo Título / Nombre Autor(es) Año
Mezigdomide (MEZI) Plus Dexamethasone (DEX) in patients (PTS) with relapsed/refractory multiple myeloma (RRMM): results from the dose-expansion phase of the CC-92480-MM trial Bahlis N, Trudel S, Quach H..., Casas-Aviles I 2023
Midostaurin plus 7+3 or Quizartinib plus 7+3 in FLT3-ITD mutated AML Torno M, Día Beya M, Fenández Moreno A..., Bergua Burgues JM 2023
Incidence, risk factors and outcomes od second neoplasm in patients with acute promyelocytic leukemia: the PETHEMA -PALG experience Sobas M, Knopinska-Posluszny W, Bergua Burgues JM, Rodríguez-Veiga R, Cano Ferri I..., Montesinos P, et al 2023
Update results of VEN-A-QUI study: a phase 1-2 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: Azacitidine or low-dose Cytarabline with Venetoclax and Quizartinib Bergua Burgués JM, Rodríguez-Veiga R, Cano Ferri I..., Montesinos P 2023
Preliminary results of QUIWI: a double blinded, randomized clinical trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD wild- type AML Montesinos P, Rodríquez-Veiga R, Bergua Burgues JM, Algarra L..., Labrador J 2023
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO Martín García-Sancho A, Baile M, Dlouhy I, Sancho JM..., Bergua J 2023
Safety and efficacy of tafasitamab ± lenalidomide added to first-line R?CHOP for DLBCL: Phase 1b First-MIND study Belada D, Kopeckova K, Bergua Burgués JM, Stevens D, André M, Pérez Persona E, et al 2023
Multi-center evaluation of light transmission platelet aggregation reagents: Communication from the ISTH SSC Subcommittee on Platelet Physiology Alessi MC, Coxon C, Ibrahim-Kosta M, Bacci M, Voisin S..., Bermejo N, et al 2023
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry Bernal T, Fernández Moreno A, LaIglesia A de, Benavente C..., Bergua Burgués JM 2023
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Rodriguez-Arboli E..., Bergua J, et al 2023